Skip to main content

Lexicon Reports Weak Q3 Revenues, Surging Loss

NEW YORK, Oct. 31 - Lexicon Genetics yesterday reported a significant fall in total third-quarter revenue atop a strong jump in R&D spending and a surge in net loss.


Revenues for the period ended Sept. 30 were $8 million, compared with $13.5 million during the same quarter one year ago, Lexicon said .


R&D spending in the quarter increased to $19.8 million from $15 million one year ago.


As a result, net loss ballooned to $16.8 million, or $.32 per share, from $6.2 million, or $.12 per share, in the third quarter 2001, the company said.


Lexicon Genetics said it had roughly $119.6 million in cash and investments as of Sept. 30.


Click here for more information.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.